The Role of PD-1 Inhibitors in the DMMR Population

We see this higher rate of response with the PD-1 inhibitors rather than PD-L1. And we carry this forward when we think about these first line trials I'm going to be discussing. GY018 and Ruby are the ones that were presented in the New England Journal. LEPO-01 is a trial we're really excited about, which is L'Havatte de Pemelizumab up front versus carboplatin-pacletaxal. C-93 is looking at maybe just using checkpoint aloe for the DMMR population.